Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

NEW YORK, June 30, 2020 /PRNewswire/ --Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG ("Novartis" or "the Company") (NYSE: NVS). Investors who purchased Novartis securities are encouraged to obtain...

NVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG and Encourages Investors to Contact the Firm

AbbVie

Amgen

AstraZeneca

Bristol-Myers

Eli Lilly

Pfizer

The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

Canada federal court dismisses drugmakers' plea challenging drug price rules

Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.

Novartis Gets Positive CHMP View for Cosentyx Label Expansion

Takeda Pharmaceutical

Swedish drugmaker, Novartis (SWX: NOVN), said last week that it will no longer seek European approval for Xiidra (dry-eye drug). According to Takeda Pharmaceutical (TYO: 4502), Novartis decision is expected to result in a £162.50 million of operating loss for the Japanese multinational pharmaceutical company.

Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra

Takeda Pharmaceutical Co Ltd said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.

Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders. On June 25, 2020, the Company agreed to pay $225 million in criminal fines and disgorge $112 million in settling bribery allegations brought forth by the U.S. Department of Justice and th

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS

Swiss drugmaker Novartis , fresh from settling U.S. charges over alleged kickbacks to doctors, is preparing for a key meeting next week with U.S.

Novartis faces key meeting in U.S. bribery scandal after settling corruption case

Swiss drug company Novartis AG NVS, +0.90% has settled with the U.S. Department of Justice and the Securities and Exchange Commission on charges made under the Foreign Corrupt Practices Act (FCPA) relating to the company and certain subsidiaries.

UPDATE: Swiss drug company Novartis settles with DoJ, SEC in case brought under Foreign Corrupt Practices Act

Novartis AG and a former unit will pay more than $346 million to resolve U.S. criminal and civil charges they bribed doctors, hospitals and clinics to prescribe their drugs and use their surgical products, U.S.

Novartis, former unit to pay $346 million to resolve U.S. bribery charges

Swiss drug company Novartis AG NVS, +0.68% has settled with the U.S. Department of Justice and the Securities and Exchange Commission on charges made under the Foreign Corrupt Practices Act relating to the company and certain subsidiaries.

Swiss drug company Novartis settles with DoJ, SEC in case brought under Foreign Corrupt Practices Act

The move hastens the demise of the malaria drug as a potential treatment for the disease.

Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

Novartis Discontinues HCQ Study Due to Enrollment Challenges

Teva Pharmaceutical

It's a face-off between an incredibly cheap stock and a pharmaceutical giant.

Better Buy: Novartis vs. Teva Pharmaceutical

Grifols, S.A.

Each company has a triad of COVID-19 projects, but they aren't in direct competition.

Better Coronavirus Stock: Grifols or Novartis?

Novartis (NYSE: NVS) shares are trading higher on Wednesday after the company announced it received FDA approval for its Cosentyx for a new indication to treat active non-radiographic axial spondyloarthritis.

Why Novartis Stock Is Trading Higher Today

Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).

Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication

Mylan

The agency found no evidence to support the theory that the antimalarial drugs touted by President Trump are effective against the coronavirus.

FDA Revokes Emergency Use Authorization for Hydroxychloroquine and Chloroquine as COVID-19 Treatments

Novartis' (NVS) ophthalmology drug, Beovu, gets update for safety information regarding retinal vasculitis and retinal vascular occlusion.

Novartis' (NVS) Beovu Gets FDA Approval for Label Update

Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.

Novartis' Asthma Treatment Meets Primary Endpoint in Phase III

Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.

Novartis (NVS) Announces Positive Data From Cosentyx Study

The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

Swiss drugmaker Novartis will start producing a genetic coronavirus vaccine this month under a deal with Massachusetts researchers. AveXis, Novartis’s gene-therapy arm, agreed to manufacture the vaccine being developed by Massachusetts Eye and Ear and Massachusetts General Hospital.

Novartis will start making coronavirus vaccine this month

A subsidiary of the pharmaceutical giant will soon ramp up production of the nonprofit hospital's SARS-CoV-2 vaccine candidate, which has yet to enter human clinical trials.

Novartis to Manufacture Mass General's Coronavirus Vaccine Candidate

Q1 GDP, Durable Goods and, of course, Initial Jobless Claims all hit the tape an hour before the bell, along with a new COVID-19 vaccine candidate and an executive order on social media.

News for Novartis Stock (NVS)